Aclaris Therapeutics, Inc. 8K

Aclaris Therapeutics reported Q2 2026 results, detailed progress and timelines across its ATI-052, bosakitug, modzatinib, and ATI-9494 programs, raised additional equity capital, and projects liquidity sufficient to fund operations through 2028.

On August 6, 2026, Aclaris Therapeutics, Inc. reported its second quarter 2026 financial results and provided a corporate and clinical update, highlighting positive full top line Phase 1a SAD/MAD results for its bispecific antibody ATI-052 supporting extended dosing, reaffirmed timelines for second-half 2026 top line readouts from Phase 1b proof-of-concept trials of ATI-052 in asthma and atopic dermatitis and a Phase 2 trial of bosakitug in atopic dermatitis, and plans to initiate Phase 2b programs for ATI-052 and modzatinib and to file an IND for ATI-9494 in the fourth quarter of 2026; the company reported a Q2 2026 net loss of $21.5 million on $1.6 million of revenue, ended June 30, 2026 with $170.6 million in cash, cash equivalents and marketable securities, subsequently raised $40.2 million via an at-the-market equity program, and believes its cash resources will fund operations through the end of 2028.

Filing Facts

CIK

1557746

Ticker

ACRS

Form

8K

Source Type

fda

Accession

0001104659-26-091629

Alert Tier

6